Cart
sales@molnova.com
Elezanumab
CAS No. 1791416-49-3
Elezanumab( —— )
Catalog No. M36747 CAS No. 1791416-49-3
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 655 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1577 | In Stock |
|
| 50MG | 2074 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElezanumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionElezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, with an IC50 of approximately 97 pM.
-
DescriptionElezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.
-
In Vitro——
-
In VivoAnimal Model:Female Lewis rat optic neuritis modelsDosage:1, 3, or 10 mg/kg Administration:IV; once a week for 5 doses Result:Protected against the optic nerve inflammationinduced RNFL degeneration.Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGF-beta/Smad
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1791416-49-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
pep2-SVKI
Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD).
-
ms48107
MS48107 is a potent and selective positive allosteric modulator of G protein-coupled receptor 68 (GPR68). It is selective for GPR68 over the closely related proton GPCRs, neurotransmitter transporters, and hERG ion channels. It can readily cross the blood-brain barrier (BBB) in mice.
-
GLP-2 (1-34) (human)
GLP-2 (1-34) (human) is a polypeptide released from the intestine within minutes after food intake. GLP-2 (1-34) (human) can be used for the research of bone remodeling processes.
